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Hepatic arterial floxuridine as second-line treatment for
systemic fluorouracil resistant colorectal liver
metastases
C Fordy, C Glover, MM Davies and TG Allen-Mersh
Department of Gastrointestnal Surgery. Impenal College School of Medicine. Chelsea and Westminster Hospital. London. UK
Summary Hepatic arterial floxundine (HAI) in 35 patients with systemic fluorouracilfolinic acid-resistant colorectal liver metastases achieved
a 140o partial response and 260o disease stabilization rate. with a median response duration of 7 months from onset of HAI.
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S\ stemic fluorouraciUfolinic acid chemotherapy is the current
standard treatment for unresectable colorectal liver metastases
Nordic Gastrointestinal Tumour AdjuvantTherapy Group. 19921
Howexer. virtuallv all colorectal lixer metastases become resistant
.Adx-anced Colorectal Cancer Meta-analv-sis Project. 1992). and
man! patients then seek second-line treatments to prolong disease
control.
There are no second-line chemotherapies of proven survival or
quality of life benefit in colorectal cancer. Hepatic arterial floxuri-
dine infusion (HAI) in patients with untreated colorectal lixer
metastases Piedbois et al. 1996W produces a higher partial
response rate 140c%) than with bolus systemic tluorouracilUfolinic
acid administration (23c c). Thus. HAI might be a useful second-
line treatment in patients >-hose colorectal lixer metastases haxe
become resistant to sx stemic fluorouracilUfolinic acid. Response to
HAI has been reported in comparatixve studies of sx stemic xs
hepatic arterial floxuridine (Kemeny et al. 1987: Hohn et al. 1989).
in wxhich patients allo-cated to the sxstemic control arm whose
disease failed to respond were then crossed oxver to the hepatic
arterial studv arm. As a result. HAI has been recommended for
treatment of patients Xx ith sy-stemic chemotherapy-resistant lixer
metastases )Kemenv et al. 1993). Hoxexer. the extent ofbenefit in
patients xxhose colorectal lixer metastases are resistant to sxvstemic
fluorouracilUfolinic acid has not been established.
The purpose of this study xxas to determine response. toxicity.
quality of life. and duration of response to hepatic arterial floxuri-
dine. in patients xxith sxvstemic fluorouracilUfolinic acid-resistant
colorectal lixver metastases.
MATERIALS AND METHODS
All patients had progressixe disease - defined as > 25c increase in
tumour size XHavxard et al. 1977 > betxx een pre- and post-treatment
computerized tomography CT scans Dx orkin et al. 199'5) - to
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bolus sx-stemic fluorouracilUfolinic chemotherapy (O'Connell et al.
1989) after a minimum of three 4-wxeeklx courses of treatment
camed out as part of routine treatment in xarious cancer centres.
Patients underx-ent hepatic arterial cannulation. as descnrbed in
Burke et al 11995). and xxere treated xith a '8-dav re2imen of
continuous floxuridine (0.2 mg kg- bodW xxeiaht da!- ) xxith
dexamethasone 20 mo infused for 14 daxs. folloxed bx- saline for a
further 14 daxvs. xxhich xxas then repeated. The dose reduction for
toxicitv criteria has been described Allen-Mersh et al. 1994).
All patients underxent baseline xithin I xeek before hepatic
arterial cannulation) and thereafter monthlv estimation of serum
asparatate transaminase. alk-aline phosphatase. bilirubin and
carcinoembrxonic antigen ICEAI. quality of life - Sickness Impact
Profile ISIP) IBergner et al. 1981). Rotterdam Symptom Checklist
IRSC) (DeHaes et al. 1990). and Hospital Anxietx and Depression
Scale H.AD) Zigmund and Snaith. 1983) - and 4-month1v CT scan
estimation oflixer metastasis xolume Dx orkin et al. 1995).
Criteria for complete or partial response. and stable disease
xxere accordin2 to UICC recommendations )HaNxxard et al. 1977).
as modified for changes betxeen pre- and post-treatment lixer CT
scans XBuroker et al. 1994). Patients xxwere recruited betx een
October 1993 and October 1996 and folloxxed up until October
1997. Toxicitx xas defined accordin2 to WHO criteria )XNorld
Health Organization. 1979).
This study xxas approx ed by the Chelsea and Westminster
Hospital Ethics Committee.
RESULTS
Thirty-fixe patients (N/F. 19:16: median age 56.8 xears. inter-
quartile range 48.2-62.4 years: median Karnofskx score 90c%.
interquartile ranoe 90-100%-c) xxere studied. All had received bolus
sx stemic fluorouracil/folinic acid chemotherapy range 4-12
courses) during xxhich lix er metastasis progression had been estab-
lished from CT scans before and after a minimum of three courses
of treatment. No patient died xxithin 30 days of hepatic arterial
cannulation. A median of six (interquartile range 3-8.75) HAI
floxuridine courses x ere administered.
There xxas a trend. xxhich did not reach statistical si2nificance
(Wilcoxon signed-rank test. P = 0.141. toxxards an oxerall rise in
median lixer metastasis xvolume after 4 months of hepatic arterial
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floxuridine (median 357 ml. range 101-737 ml) compared %vith
baseline (333 ml. 82-738 ml). Howexver. there Awas a significant
reduction (Wilcoxon si2ned-rank test. P = 0.0071 in serum
CEA lexvel after 4 months of hepatic arterial floxuridine (median
126jg 1-'. range 11-345 pg 1-' compared wxith baseline
(279 ji 1-'. 62-1209 gcg 1-'). Partial response (>50%c reduction in
liver metastasis xolume) occurred in fixve patients. and disease
stabilization (<25%7e increase but < 50%' reduction in lixer metas-
tasis xolume) in a further nine patients. The median duration of
disease stabilization (interxal x ith CT scan lix er metastasis
Xolume <25%/ greater than baseline) Awas 7 months (range 1- 1
months). The serum CEA lex el initialiv fell belox baseline lexel in
22 patients but subsequently rose to baseline or higher by a median
of 8 months (range 3-18 months) from onset of hepatic arterial
floxuridine.
Six patients xere alixe at completion of follox-up. Oxerall
surxixal was a median of 308 daxs (range 179-560 daxs) from
hepatic arterial cannulation. Thirteen of the 29 patients xwho died
did so as a result oflixer metastasis and the remainder as a result of
extrahepatic disease progression. The proportion of days surxix ed
with an abnormal quality of life score (Bergner et al. 1981:
Zigmund and Snaith. 1983: DeHaes et al. 1990) after hepatic arte-
rial floxuridine w as a median of0%l (range 0-4.7%7c) for RSC phx s-
ical. 0%71 (0-14.5%) for RSC psychosocial. 0% (0-13.4%7) for
HAD depression. 0%c (0-9.9%,7) for HAD anxiety and 30.7%;
(13.4-51.1%ck) for SIP. The proportion of sun-ix-al with abnormal
quality of life among patients in whom anv abnormal quality of
life score occurred is showxn in Table 1. Toxicitv necessitated
temporan- dose reduction in 31 and omission in 26 patients. The
toxicity profile is shoxxn in Table 2. Sclerosing cholangitis xxas not
diagnosed in any patient.
DISCUSSION
Although all patients had receix-ed a conxentional bolus systemic
fluorouracil/folinic chemotherapy regimen (O'Connell et al.
1989). this wxas administered as routine treatment in xarious
oncology centres. and centre to centre xariation in sy stemic
chemotherapy treatment criteria may haxe been greater than
betx een centres collaboratinexA-ithin a single protocol. In addition.
higher (30-4U-c) partial response rates than with bolus systemic
fluorouracillfolinic acid can be achiex ed wxith novel schedules and
combinations of systemic fluorinated pyrimidines (Lexi et al.
1994: Tournigand et al. 1997). and the extent of HAI response in
patients whose lixer metastases are resistant to these regimens is
unknown. Thus. the present results relate to patients xx-hose lixer
metastases xxere progressing during treatment with conxentional
bolus fluorouracil/folinic acid chemotherapy administered outside
a clinical trial.
Hepatic arterial floxuridine infusion achiexes a tenfold increase
in lixer metastasis fluorinated pyrimidine concentration compared
wxith sxstemic fluorouracil infusion (Ensminger et al. 1978). The
stabilization of disease in 40c%e of cases together wxith a significant
fall in the serum tumour marker CEA (Allen-Mersh et al. 1987) for
7-8 months suggests that this increased fluorinated pynrimidine
concentration produced an anti-tumour effect in patients xxith
sy stemic fluorouracil-resistant lixer metastases. Hox exer. HAI did
not achiexe a si-nificant oxerall reduction in lixer metastasis
xolume. and the partial response rate was only 14%. This reduced
partial response rate compared x ith that (40%-r) obtained in
untreated colorectal lixer metastases (Piedbois et al 1996) may
Table 1 Proportion of survival after commencing hepatic arterial floxunrdine
(HAI) that was associated with abnormal quality of life (QoL) scores among
patients with any abnormal QoL score dunrng HAI treatment
QoL instrument Abnornal QoL score Proportion (%) survival
(no. of pabents) with abnormal QoL score
(median, range)
RSC physica 10 17.0 ( 8.6-31.7)
RSC psychosocial 14 14.9 (11.6-35.6)
HAD depression 11 29.4 (15.5-44.4)
HAD anxiety 11 14.7 (11.1-35.3)
SIP 25 44.1 (28.8-52.9)
Table 2 Number of patients experiencing toxicity. by WHO grade. after
intrahepatic floxuridine in 35 patients with systemic fluorouracil-resistant
colorectal liver metastases
Toxicity I 11 III IV
Gastritis 9 5 3 1
Nausea/vomiting 6 7 4 1
Diarrhoea 8 5 2 3
Stomatitis 6 2 3 6
result from fluorouracil-induced up-regulation of enzxmes. such
as thymidylate synthase. which modulate the cvtotoxic effect of
floxuridine (Jenh et al. 1985). Although non-fluorinated pyrimi-
dine cvtotoxics. such as the topoisomerase inhibitor irinotecan. are
more logical choices for second-line chemotherapy in fluoro-
uracil-resistant colorectal cancer (Rothenburg et al. 1996). results
currently suggest only an 18%/e partial response rate associated
xx ith a 1.9%7 incidence of fatal toxicity (Rougier et al. 1997). A
higher response rate (33%) has been reported xxith combined intra-
hepatic fluorouracil and human interferon c2b. but with grade
III/IV toxicitv in 62%=- ofpatients (Patt et al. 1997).
The monthly RSC and HAD qualitx of life (QoL) assessments
may hax-e underestimated the extent of the HAI-associated QoL
deficit compared wxith the SIP. xxhich suggested a greater QoL
abnormalitx. Any QoL deficit is also likely to haxe been underesti-
mated at the terminal stage of disease because most patients did
not complete QoL questionnaires during the month before death.
HAI patients in this study receixed intra-arterial dexamethasone
afterprexious studies (Kemeny et al. 1992) reporting reduced toxi-
city and improxed response compared wxith floxuridine alone. and
this mav hax-e influenced QoL independently of the floxuridine
effect. Despite these limitations. QoL instruments sugaested that
quality of life xas preserxed in most of the prexiously treated
patients receixinc- H-AI. The commonest QoL deficit was depres-
sion (Table 1). xhich is thought to be disease rather than toxicitx
related (Earlam et al. 1996. 1997). Grade III or IV stomatitis
affects <5%'7 of patients receixing HAI as first-line treatment
Earlam et al. 1997). but occurred in 26%/ of patients in this study
(Table 2). Thus. previous fluorouracil exposure may haxe sensi-
tized patients to dexvelop stomatitis wxith subsequent hepatic arte-
rial floxuridine.
Eighty per cent of colorectal lixver metastasis patients managed
by symptom control die from lixver metastasis progression (Allen-
Mersh et al. 1994). It is not clear wxhether a similar failure pattern
occurs in systemic fluorouracil-resistant lixer metastasis patients
subsequently managed by symptom control. Hoxxexver. the findinc
that only 45%- of our patients died of liver metastasis progression
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suggests that extrahepatic disease progressed while HAI slowed
growth in the liver. Thus. liver metastasis patients in whom
extrahepatic metastases develop slowly are likely to benefit most
from HAI.
First-line chemotherapy for colorectal liver metastases should
now involve either systemic (Levi et al. 1994; Tournigand et al.
1997) or regional (Piedbois et al. 1996) fluorinated pyrimidine
regimens. which are capable of higher response rates than are
achieved (Advanced Colorectal Cancer Meta-analysis Project.
1992) with conventional bolus systemic fluorouracil/folinic acid
(O'Connell et al. 1989). Although HAI slowed liver metastasis
progression in 40% ofpatients with systemic fluorouracil-resistant
liver metastases in this study. a more effective role is in the first-
line treatment ofselected (Burke et al. 1995. 1997) colorectal liver
metastasis patients in whom prolonged survival with sustained
QoL (Allen-Mersh et al. 1994: Earlam et al. 1997) can be
achieved.
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